Assignee
BIOGEN INT NEUROSCIENCE GMBH
CH·10 granted patents·9 pending applications·49 citations·filing 2012–2025
Top patents by PatentIndex Score
19 records- 0190US9896504B2Human anti-alpha-synuclein antibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2016·Granted Feb 20, 2018·8 cites·75 claims
- 0290US9605059B2Human anti-tau antibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2014·Granted Mar 28, 2017·12 cites·70 claims
- 0386US10259866B2TDP-43 specific binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2016·Granted Apr 16, 2019·7 cites·88 claims
- 0485US10301381B2Anti-alpha synuclein binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2018·Granted May 28, 2019·4 cites·16 claims
- 0584US9975947B2Anti-alpha synuclein binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2017·Granted May 22, 2018·4 cites·15 claims
- 0684US9587014B2TDP-43 specific binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2012·Granted Mar 7, 2017·7 cites·33 claims
- 0781US10842871B2Methods for treating Alzheimer's diseaseBIOGEN INT NEUROSCIENCE GMBH·Filed 2015·Granted Nov 24, 2020·7 cites·63 claims
- 0873US2021238265A1Human Anti-Tau AntibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2020·Application pending·0 cites
- 0969US11091540B2TDP-43 specific binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2019·Granted Aug 17, 2021·0 cites·31 claims
- 1069US10703808B2Human anti-alpha-synuclein antibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2018·Granted Jul 7, 2020·0 cites·19 claims
- 1163US2019233506A1Human Anti-Tau AntibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2018·Application pending·0 cites
- 1259US2026091109A1Method for Treating Alzheimer's DiseaseBIOGEN INT NEUROSCIENCE GMBH·Filed 2025·Application pending·0 cites
- 1358US2018002409A1Human Anti-Tau AntibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2017·Application pending·0 cites
- 1457US2018011112A1Use of an Anti-Alpha-Synuclein Antibody to Diagnose an Elevated Level of Alpha-Synuclein in the BrainBIOGEN INT NEUROSCIENCE GMBH·Filed 2017·Application pending·0 cites
- 1556US2019094245A1Use of an Anti-Alpha-Synuclein Antibody to Diagnose an Elevated Level of Alpha-Synuclein in the BrainBIOGEN INT NEUROSCIENCE GMBH·Filed 2018·Application pending·0 cites
- 1653US2022281963A1Methods for treating alzheimer's diseaseBIOGEN INT NEUROSCIENCE GMBH·Filed 2022·Application pending·0 cites
- 1744US2020377579A1Compositions and methods for treating synucleinopathiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2018·Application pending·0 cites
- 1837US2020308259A1Methods for treating alzheimer's diseaseBIOGEN INT NEUROSCIENCE GMBH·Filed 2017·Application pending·0 cites
- 1928US11340225B2Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteinsBIOGEN INT NEUROSCIENCE GMBH·Filed 2017·Granted May 24, 2022·0 cites·47 claims
Join the waitlist — get patent alerts
Get an alert when BIOGEN INT NEUROSCIENCE GMBH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →